Tuesday, January 24 2017
Myeloma Matters : January 2017
- Myeloma Canada's Patient Advisory Council (PAC) 2016 Year in Review and leadership Changes
- Health Canada has approved Revlimid® plus dexamethasone as a first-line treatment for newly diagnosed patients with multiple myeloma, not eligible for translplant.
- Revlimid® as first-line treatment for non-transplant eligible myeloma patients now funded in Newfoundland and New Brunswick
- Volunteer with the 2017 Multiple Myeloma
- Donate a car to Myeloma Canada, it won't cost you a penny!